Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Sales and Divestitures (2020 - 2025)

Adma Biologics' Gains from Sales and Divestitures history spans 6 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 0.61% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, down 0.61%, while the annual FY2025 figure was $1.9 million, 0.61% down from the prior year.
  • Gains from Sales and Divestitures reached $1.9 million in Q4 2025 per ADMA's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.7 million in Q4 2022 to a low of $87750.0 in Q2 2021.
  • Average Gains from Sales and Divestitures over 5 years is $1.1 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 2840.61% in 2022, then tumbled 56.02% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $92750.0 in 2021, then soared by 2840.61% to $2.7 million in 2022, then crashed by 56.02% to $1.2 million in 2023, then soared by 57.28% to $1.9 million in 2024, then decreased by 0.61% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Gains from Sales and Divestitures are $1.9 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025).